Loading...
OTCM
MDGEF
Market cap1mUSD
May 14, Last price  
0.10USD
Name

Medigene AG

Chart & Performance

D1W1MN
OTCM:MDGEF chart
P/E
—
P/S
0.19
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.74%
Rev. gr., 5y
-4.89%
Revenues
6m
-80.69%
12,501,00019,555,00030,549,00022,058,00033,507,00037,859,0002,214,0002,300,0005,869,0007,548,00012,581,0003,101,0004,101,0007,676,0007,576,00010,511,0008,002,00010,463,00031,247,0006,034,000
Net income
-16m
L+94.20%
-12,666,000-12,045,000-6,891,000-29,876,000-30,790,000-21,962,000-17,869,0006,281,000-14,877,000-10,282,000-5,757,000-12,999,000-9,492,000-13,573,000-21,226,000-19,962,000-28,875,000-9,983,000-8,330,000-16,177,000
CFO
-15m
L
-12,096,000-10,437,000-1,330,000-32,100,000-25,856,000-18,801,000-11,411,0006,864,000-6,507,000-12,246,000-8,756,000-10,605,000-3,758,000-20,849,000-10,142,000-16,423,000-24,786,000-10,754,00011,976,000-15,119,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Medigene AG is a biotechnology firm dedicated to pioneering T cell immunotherapies aimed at combating cancer. Its primary therapeutic thrust involves personalized T cell-based treatments, specifically T cell receptor-modified T cells, which are currently undergoing clinical trials to address significant unmet medical needs. Beyond this core focus, Medigene also explores dendritic cell vaccines and specialized T cell monoclonal antibodies. Diverging from oncology, the company is additionally engaged in the development and commercialization of RhuDex for applications in hepatology and gastroenterology. Collaborations are key to Medigene's strategy; it maintains a strategic alliance with 2seventy bio, Inc. for advancing T cell receptor research. Furthermore, research cooperation agreements are in place with the Université de Montréal and Cytovant Sciences Co. Ltd. to discover and develop novel cancer antigens for immunotherapy. Established in 1994, the company's headquarters are located in Munich, Germany, with its operational footprint spanning Europe, the United States, Asia, and other international regions.
URL
https://www.medigene.de/
IPO date
Jun 30, 2000
Employees
87
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT